Clinical Trial Update: 22 G - 25 G SINS Trial for Pancreatic Masses [NA]

View source ↗

Summary

Clinical trial NCT02424838 (22G-25G SINS Trial for pancreatic masses) sponsored by AdventHealth has completed. The study concerns pancreatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: AdventHealth | Conditions: Pancreatic Neoplasms | NA | Status: COMPLETED